NTT-DOCOMO
20.1.2023 09:01:39 CET | Business Wire | Press release
NTT DOCOMO, INC. announced today that it will organize a full-scale booth at MWC Barcelona 2023, the world’s largest mobile-related exhibition, in Barcelona, Spain from February 27 to March 2.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230120005094/en/
NTT DOCOMO Booth at MWC Barcelona 2023 (Graphic: Business Wire)
The DOCOMO booth, which will showcase exhibitions and presentations focused on the main themes of 6G, open radio access networks (Open RAN) and extended reality (XR), will also promote international standardization and global business for next-generation communication technologies. Due to the global pandemic, this will be DOCOMO’s the first onsite appearance at MWC Barcelona since 2019.1
In the 6G section, DOCOMO will present the coming 6G world and advanced wireless technologies that the company is currently developing. This will include a demonstration of the Human Augmentation Platform to communicate haptic sensations between people connected to a 6G network to enable, for example, a musical student to mimic the exact finger motions of a teacher.
In the Open RAN section, DOCOMO will present experiential content to help visitors understand the concept and structure of Open RAN, as well as progress being achieved to enable multi-vendor telecommunication equipment2 to be combined in Open RAN, as well as related collaborations with international carriers.
In the XR section, visitors will experience the metaverse filled with music, anime and movies and also a virtual-live system, both provided by NTT QONOQ, INC., a company launched by DOCOMO’s parent NTT group last October to promote XR business.
Through this exhibition, DOCOMO looks forward to globally communicating its advanced technologies and businesses under the company’s brand slogan “changing worlds with you.”
For more about DOCOMO’s exhibits and the overall exhibition, please refer to the appendix.
1 DOCOMO organized an exhibition in Japan in 2021 and then one online in 2022.
2 Creation of 5G Open RAN Ecosystem to Accelerate Adoption of Open RAN by Operators Globally”
https://www.docomo.ne.jp/english/info/media_center/pr/2021/0208_00.html
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 85 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
Appendix
Overview of NTT DOCOMO Booth at MWC Barcelona 2023
1. Exhibitions
Theme |
Exhibits |
Contents |
6G |
Human Augmentation Platform |
As an example of this 6G application, presenters will use haptic information to teach musical techniques and guide a robot in whisking green tea. |
Wireless Technologies |
DOCOMO’s technical approaches to the realization of 6G will be introduced with detailed explanations. |
|
Open RAN |
Interactive Contents |
Experiential content in the form of a simulation game will allow visitors to grasp the overview and structure of Open RAN. |
Shared Open Lab
|
This Open RAN verification facility located at the DOCOMO R&D Center in Japan will be introduced in 3D. |
|
XR |
XR World |
This metaverse diorama will enable people to view a life-size Godzilla from various angles. |
Matrix Stream |
Presenting NTT QONOQ’s virtual-live and general-purpose video-delivery system for extended reality |
|
Mixed Reality Animals—Volumetric Video × Magic Leap 2 |
Videos of real cats and penguins will be converted to 3DCG and projected into real space using a Magic Leap 2 MR headset. |
2. NTT DOCOMO Booth Location
4E50, Hall 4
3. Presentations
1 |
Broadcast Stage
|
2 |
5G Futures Summit
|
Note: The content and schedule of the presentations are subject to change. Please check the official website of MWC Barcelona 2023 for the latest information.
Reference
MWC Barcelona 2023
1. Dates & Times
Monday, February 27 to Thursday, March 2
08:30 to 19:00, except last day from 08:30 to 16:00 (all times local)
2. Venue
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain
3. Official Website
https://www.mwcbarcelona.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230120005094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom